Form 4: Corcept Therapeutics Director Daniel N. Swisher Jr. Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Summary

• On June 3, 2024, Daniel N. Swisher Jr., a director of Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $5.86 per share.
• Simultaneously, Swisher sold 2,200 shares of common stock at a price of $30.21 per share.
• The transactions were executed under a pre-existing 10b5-1 trading plan.
• Following these transactions, Swisher directly owns 0 shares of Corcept Therapeutics common stock.
• Swisher also owns 2,350 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative outlook.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and large shareholders) buy or sell their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information at the time of the trades.

Key Dates